Edible Garden (EDBL) Q1 2026 Earnings Transcript

Edible Garden reported Q1 revenue of $3.3 million, up 22.9% year over year, driven by 45.9% growth in cut herbs, 27% growth in vitamins and supplements, and 50% international sales growth. The company’s retail network now exceeds 6,000 locations, while management is shifting investment toward higher-margin RTD and shelf-stable nutrition products, with co-manufacturer production expected to begin in September. However, operating expenses rose to $10 million from $5.6 million and net loss widened to $3.7 million despite a $3.4 million nonrecurring tax benefit.

Analysis

The incremental signal here is not the headline growth rate; it is the company’s pivot from a working-capital constrained fresh-food operator into a retailer-led platform for shelf-stable, higher-velocity SKUs. If management is right about RTD demand, the economics can change materially because shelf-stable inventory reduces spoilage risk, expands distribution radius, and creates a more scalable national sales model than the greenhouse business. The market is likely underestimating how much leverage a successful RTD launch could create to the existing retail footprint: the same doors can now carry multiple categories, so future growth is more about share-of-shelf than store count.

The biggest second-order effect is on suppliers and channel partners. Near-term co-manufacturer capacity tightness suggests this is less about optionality and more about whether the company can lock in production before competitors or larger brands crowd the same white space. That creates asymmetric benefits for distributors with established shelf access, while putting pressure on smaller fresh/organic names whose sell-through may be diluted as retailers reprioritize better-for-you and functional beverages with higher ring and better margin. KR and WMK are modest indirect beneficiaries from mix expansion, while PSMT looks like the cleanest international exposure to the same theme.

The key risk is that the story outruns the balance sheet before RTD economics are proven. Cash remains thin relative to execution needs, and the transition requires capex, working capital, and flawless launch timing over the next 2-3 quarters. If prototype-to-production slips beyond the current window or if the co-man hits capacity before repeat orders convert, the equity likely re-rates sharply lower because the current narrative premium is doing most of the work.

Contrarian take: the market may be too focused on near-term losses and not enough on the optionality embedded in retailer pull-through. But the flip side is that a lot of the current enthusiasm is narrative-driven, not yet evidence of durable margin improvement. In other words, the stock can stay disconnected from fundamentals for a while, but the burden of proof shifts to July-September execution, not this quarter’s top-line momentum.

Key Decisions for Investors

• Long EDBLW only as a tactical option on RTD execution: buy on post-print weakness and hold through the mid-July prototype update; upside is meaningful if the September co-man launch validates demand, but risk is a fast drawdown if timing slips.
• Pair trade: long PSMT / short EDBLW for the next 2-3 quarters if you want exposure to the same Caribbean/South America growth vector without single-name execution risk; PSMT offers cleaner earnings quality and lower funding risk.
• Tactically overweight KR and WMK on a 1-2 quarter view as incremental channel beneficiaries of wider shelf-stable assortments and private-label adjacency; risk/reward is modest but more defensible than the microcap direct play.
• Avoid chasing EDBLW into strength until there is proof of repeatable RTD production and retail velocity; if co-man capacity is reached before meaningful replenishment orders, the stock could give back a large portion of the rerating within weeks.
• For high-risk accounts, consider a small call spread in EDBLW into the September manufacturing window; this gives convexity to a successful launch while capping downside to premium paid.